



Policy: Publicly Funded Vaccine Eligibility for Individuals at High Risk of Acquiring Vaccine Preventable Diseases

Originating Branch: Public Health Branch

Original Approval Date: January 20, 2011 **Effective Date:** July 6, 2015

Approved By:

Dr. Jesse Kancir
Deputy Chief Medical Officer of Health, Health and Wellness

September 22, 2025

Version

1. POLICY STATEMENT

- 1.1. The Nova Scotia Department of Health and Wellness (DHW) recognizes the need to provide immunizations to individuals at high risk of acquiring vaccine preventable diseases, which may not be included in the routine immunization schedule.
- 1.2. DHW is committed to a safe and consistent approach to providing publicly funded immunizations to high-risk individuals.
- 1.3. Providing immunization to residents of Nova Scotia is a responsibility shared between DHW, the Nova Scotia Health Authority (NSHA), the Izaak Walton Killam Health Centre (IWK), primary care providers and health care organizations.
- 1.4. DHW provides policies, standards, and guidelines for each of the immunization programs and procures the immunization products to be included in the publicly funded program.
- 1.5. NSHA, the IWK, primary care practitioners and health care organizations implement the programs to Nova Scotians in adherence with those policies, standards, and guidelines.

2. DEFINITIONS

- 2.1. **Youth congregate living setting:** an institutional residence/dormitory with 13 or more residents (where all or majority are youth and not related) and such residents live and use shared spaces such as common sleeping areas, bathrooms, kitchens.
- 2.2. **Groups at high risk of vaccine preventable diseases:** A group of individuals with one or more of the conditions or other eligibility criteria noted in [Appendix A](#)
- 2.3. **Individuals at high risk of vaccine preventable diseases:** A person with one or more of the conditions or other eligibility criteria noted in [Appendix A](#)
- 2.4. [Federal Government Immigration and Citizenship Glossary](#)

3. POLICY OBJECTIVES

- 3.1. To protect residents of Nova Scotia or those who are establishing residency in NS who are at a higher risk of vaccine preventable diseases.
- 3.2. To provide guidance for public health providers and other immunization providers to identify which immunizations are publicly funded in Nova Scotia for individuals at high risk of acquiring vaccine preventable diseases.
- 3.3. To provide access to publicly funded vaccines to those individuals at high risk who have become residents of Nova Scotia and started an immunization series out of province:
 - Will complete the series as part of the Nova Scotia publicly funded immunization program
 - Will follow the same publicly funded eligibility as residents of Nova Scotia, regardless of previous province/territory eligibility.
- 3.4. This policy does not provide information on scheduling, dosing, and frequency. It is expected that the client's healthcare provider will have consulted with the [Canadian Immunization Guide](#), a specialist or specialized care team to determine the schedule, dosing and frequency of the immunizations.

4. APPLICATION

- 4.1. This policy applies to all public health and other immunization providers who provide publicly funded immunizations.

5. POLICY DIRECTIVES

- 5.1. Upon request from a family physician, nurse practitioner, specialist, specialized care team or public health practitioner, an immunizing product will be provided to an individual at high risk, as per [Appendix A](#).
- 5.2. The decision to immunize will depend on a thorough case by case analysis of risks and benefits.

Eligibility (refer to the [Publicly Funded Vaccine/Immunoglobulin Policy](#) for more information).

- 5.3. Residents of Nova Scotia
 - 5.3.1 All residents of Nova Scotia with a valid Nova Scotia health card are eligible to receive publicly funded immunizations as described in [Appendix A](#).
- 5.4. Visitors, Temporary Residents, Non-Residents, Canadian Post-Secondary Students and Newcomers (immigrants, refugees, and others establishing residency in Nova Scotia).
 - 5.4.1 Newcomers who are establishing residency in Nova Scotia, and refugees that did not receive immunizations as part of the [Interim Federal Health Program](#) are eligible to receive them according to this policy. This includes individuals establishing residency who are awaiting a Nova Scotia health card.
 - 5.4.2 Canadian residents are eligible to receive immunizations as per home province or territory's immunization schedule providing those immunizations are publicly funded in Nova Scotia.
 - 5.4.3 Immunizations, except for the influenza vaccine and COVID-19 vaccine are not routinely provided through the publicly funded immunization program to visitors, temporary residents of Nova Scotia, international students who are not establishing residency, or temporary foreign workers.
 - 5.4.4 In unusual circumstances, following a risk assessment in consultation with the Medical Officer of Health, an individual non-resident determined to be at high risk may be eligible to receive specific immunizing products as described in [Appendix A](#).

6. POLICY GUIDELINES

- 6.1. [Appendix A](#) serves as a guideline for healthcare providers to identify a client's eligibility for specific immunizing products based on their high-risk condition or other eligibility criteria.
- 6.2. The degree of impaired immunity may range from insignificant to profound and should be taken into account when considering an immunization schedule for the immune compromised client.
- 6.3. Whenever possible, eligible individuals should be immunized before immune suppressing treatments and/or transplantation are undertaken.

7. ACCOUNTABILITY

- 7.1. For the purpose of the administration of this policy, accountability is delegated to the Deputy Minister of Health and Wellness.
- 7.2. DHW Public Health has a responsibility to ensure the policy is current, evidence informed and reviewed every two years. DHW is also accountable to communicate the policy to immunization providers and for on-going monitoring and enforcement of this policy.
- 7.3. The NSHA and the IWK are accountable to ensure this policy is communicated and adhered to by their staff
- 7.4. Public Health staff and other healthcare providers who provide publicly funded immunizations are responsible for adhering to this policy.

8. MONITORING / OUTCOME MEASUREMENT

- 8.1. DHW Public Health is responsible for defining strategic outcomes, and monitoring performance and effectiveness of this policy.
- 8.2. The NSHA and the IWK are responsible for monitoring the implementation of this policy.

9. REPORTS

- 9.1. N/A

10. REFERENCES

- 10.1. Infectious Disease Expert Group, 2018
- 10.2. Province of Nova Scotia (2023) Nova Scotia Publicly Funded Vaccine/Immunoglobulin Eligibility Policy.
Retrieved from <https://novascotia.ca/dhw/CDPC/info-for-professionals.asp>
- 10.3. Public Health Agency of Canada. Canadian Immunization Guide. Retrieved from <https://www.canada.ca/en/public-health/services/canadian-immunization-guide.html>
- 10.4. Public Health Agency of Canada. National Advisory Committee On Immunization. Retrieved from: <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci.html>

11. APPENDICES

- 11.1. [Appendix A](#): Immunization Eligibility for Individuals at High Risk of Acquiring Vaccine Preventable Diseases

12. VERSION CONTROL

Version	September 22, 2025, replaces all previous versions.
----------------	---

13. INQUIRIES

Health Protection, Public Health Branch
Nova Scotia Department of Health & Wellness
Email: cdpc@novascotia.ca

APPENDIX A: Publicly Funded Immunization Eligibility for Individuals at High Risk of Acquiring Vaccine Preventable Diseases

For schedule and dosing recommendations, consult the Canadian Immunization Guide and/or a specialist or specialized care team member.

Refer to the [Publicly Funded Vaccine/Immunoglobulin Policy](#) for more information.

IMMUNE SYSTEM	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Cancers				✓ ¹						✓			
Congenital immunodeficiency			✓ ²	✓		✓	✓ ³			✓ ⁴			
Hematopoietic stem cell transplant ⁵	✓		✓ ²	✓		✓	✓ ³	✓ ⁶		✓			✓ ⁶
HIV		✓ ⁷	✓ ²		✓ ⁸	✓	✓ ³	✓ ⁶		✓			✓ ⁶
Immunosuppressive therapy						✓ ⁹	✓ ^{3,9}	✓ ^{6,10}		✓ ¹¹			✓ ^{6,10}
Solid organ transplant			✓ ²	✓ ¹²		✓	✓ ³	✓ ^{6,10}		✓			✓ ^{6,10}
Severe immunodeficiency												✓ ¹³	

BLOOD AND SPLEEN	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Splenic disorders, including asplenia, sickle cell disease, or other hemoglobinopathies			✓ ¹⁴	✓		✓	✓ ¹⁵			✓			✓
Hemophilia and other bleeding disorders			✓										
Receiving repeated replacement of plasma-derived clotting factors		✓ ¹⁶											

¹ Malignant hematological disorders only (e.g., leukemia, lymphomas).

² Immunization with a higher dose of monovalent Hep B vaccine is recommended (e.g., Recombivax Dialysis).

³ Quadrivalent products vary. Ensure appropriate product for those less than two years of age.

⁴ Involving any part of the immune system, including B-lymphocyte immunity, T-lymphocyte mediated immunity, complement system (e.g., properdin or factor D deficiencies).

⁵ HSCT recipients should be viewed as 'never immunized' and require complete reimmunization post transplantation. DTap-IPV-Hib is recommended for adults and children (expert opinion).

⁶ MMR and varicella vaccines should be given only when the client is immunocompetent, as determined by their health care provider.

⁷ The individual at high risk and children 6 months to less than 3 years of age living in the same household are eligible.

⁸ Less than 46 years of age.

⁹ Only persons with acquired complement deficiency due to receipt of the terminal complement inhibitor eculizumab (Soliris).

¹⁰ MMR and varicella vaccine should be given at least 4 weeks before solid organ transplantation or initiation of immunosuppressive therapy.

¹¹ Including use of long-term corticosteroids, chemotherapy, radiation therapy and post-organ transplant therapy.

¹² Lung transplants only.

¹³ Children less than 2 years of age. For interpretation, refer to [CIG](#).

¹⁴ Recommended for conditions requiring repeated transfusions (e.g., sickle cell disease).

¹⁵ Quadrivalent products vary. Ensure appropriate product for those less than two years of age.

¹⁶ The individual at high risk and children 6 months to less than 3 years of age living in the same household are eligible.

APPENDIX A: Publicly Funded Immunization Eligibility for Individuals at High Risk of Acquiring Vaccine Preventable Diseases

For schedule and dosing recommendations, consult the Canadian Immunization Guide and/or a specialist or specialized care team member. Refer to the [Publicly Funded Vaccine/Immunoglobulin Policy](#) for more information.

RESPIRATORY	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Chronic lung disease										✓ ¹		✓ ²	
Cystic fibrosis										✓		✓ ³	✓
Severe congenital airway anomalies												✓ ⁴	
CARDIAC	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Heart disease										✓			
Hemodynamically significant chronic cardiac disease												✓ ⁵	
Chronic Salicylic Acid Therapy													✓
NEUROLOGICAL/NEURODEVELOPMENTAL	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Chronic neurological conditions impairing clearance of secretions										✓		✓ ⁶	
Down syndrome												✓ ⁷	
HEPATIC AND RENAL	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Chronic liver disease		✓ ⁸	✓							✓ ⁹			
Chronic renal disease			✓ ¹⁰							✓			✓

¹ For those with asthma, eligibility includes children 2 months to less than 18 years requiring acute medical care in the past 12 months and adults 50 to less than 65 years with asthma requiring treatment within the past 12 months.

² Children less than 2 years of age. Chronic lung disease, including bronchopulmonary dysplasia, requiring ongoing assisted ventilation, oxygen therapy, or chronic medical therapy in the 6 months prior to the start of the RSV season.

³ Children less than 2 years of age. Cystic fibrosis with respiratory involvement and/or growth delay.

⁴ Children less than 2 years of age. Severe congenital airway anomalies impairing clearing of respiratory secretions.

⁵ Children less than 2 years of age. Requires ultrasound for diagnosis.

⁶ Children less than 2 years of age. Neuromuscular conditions impairing clearing of respiratory secretions.

⁷ Children less than 2 years of age born during or entering their first RSV season. If they have another high-risk condition, they can receive it during their second RSV season.

⁸ The individual at high risk and children 6 months to less than 3 years of age living in the household are eligible.

⁹ Including hepatic cirrhosis and biliary atresia.

¹⁰ Immunization with a higher dose of monovalent Hepatitis B vaccine is recommended (e.g., Recombivax Dialysis).

APPENDIX A: Publicly Funded Immunization Eligibility for Individuals at High Risk of Acquiring Vaccine Preventable Diseases

For schedule and dosing recommendations, consult the Canadian Immunization Guide and/or a specialist or specialized care team member.

Refer to the [Publicly Funded Vaccine/Immunoglobulin Policy](#) for more information.

OTHER CHRONIC CONDITIONS	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Chronic cerebrospinal fluid leak										✓			
Cochlear implants (including scheduled for implant)				✓						✓			
Diabetes										✓			

PREMATURITY	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Premature infants (<37 weeks gestational age at birth during their first RSV season)												✓	

LIVING SITUATION	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
Residents of long-term care facilities										✓	✓ ¹		
Living in residential care for children with complex medical needs										✓			
Living in communities/settings with sustained high rates of invasive pneumococcal disease										✓ ²			
Youth <26 years moving into youth congregate-living settings for the first time						✓ ^{3,4,5}							
Homelessness										✓			

¹ Individuals 60 years and older living in a licensed long term care facility and hospital inpatients 60 years and older awaiting placement.

² As determined by Public Health.

³ Entering post-secondary studies and living in congregate-living.

⁴ First time military trainees who will be living in a military congregate-living setting.

⁵ Those living in a youth congregate living setting not otherwise defined (e.g., Nova Scotia Youth Centre, youth community residential setting, or youth shelter).

APPENDIX A: Publicly Funded Immunization Eligibility for Individuals at High Risk of Acquiring Vaccine Preventable Diseases

For schedule and dosing recommendations, consult the Canadian Immunization Guide and/or a specialist or specialized care team member.

Refer to the [Publicly Funded Vaccine/Immunoglobulin Policy](#) for more information.

PERSONAL AND OCCUPATIONAL	DTap-IPV-Hib	Hep A	Hep B	Hib	HPV	Men B	Men-C-ACWY	MMR	Mpox	Pneu-C-20	RSV	RSVAb	Varicella
High-risk sexual practices		✓ ¹	✓						✓ ^{2,3}				
Two-Spirit, MSM*, and Transgender^ People <ul style="list-style-type: none"> *Men who have sex with men (MSM): men who engage in sexual activity with other men, regardless of sexual orientation or identity. ^Transgender people: individuals who identify as trans men, trans women, trans masculine, trans feminine, non-binary, gender-fluid, intersex, and other gender-diverse persons. 		✓ ¹	✓		✓ ⁴				✓ ⁵				
Staff or volunteers in sex-on-premises venues									✓ ⁶				
Substance use or harmful alcohol use		✓ ¹	✓							✓			
Smoking										✓ ⁷			
Health care professionals working in, or persons visiting friends/relatives in mpox outbreak zone within impacted African countries where there is a level 2 travel health notice for mpox .									✓				

¹ The individual at high risk and children 6 months to less than 3 years of age living in the household are eligible.

² Sex workers regardless of gender, sex assigned at birth, or sexual orientation, or those planning to engage as a sex worker.

³ Those who engage in sex tourism regardless of gender, sex assigned at birth, or sexual orientation.

⁴ Less than 46 years of age.

⁵ Two-Spirit, MSM, and Transgender People who meet one or more of the following criteria: Have more than one sexual partner; are in a relationship where at least one of the partners has other sexual partners; have confirmed bacterial sexually transmitted infection acquired in the last year; have engaged in sexual contact in sex-on-premises venues. Sexual partners of individuals who meet these criteria are also eligible.

⁶ Where workers may have contact with fomites potentially contaminated with mpox.

⁷ Adults aged 50 to 64 years.